REGISTER 03 · THE DOSE RECORD
BPC-157 TB-500 Dosage: What the Studies Administered
Research-context only. Animal doses by body weight, routes, and reconstitution practice — never a human protocol.
BPC-157 TB-500 Dosage in the Research Literature
BPC-157 TB-500 dosage, as a single number for the blend, does not exist in the peer-reviewed literature. There is no validated dose for the combination in any species, and no controlled combination dose-finding study has been published [9]. What exists are doses for each constituent studied separately, almost entirely in animals, plus a packaging convention for commercial vials. This page describes those research doses and routes. It is not a protocol, and nothing here is a human dosing recommendation.
The constituent figures are these. BPC-157 in rodent studies is commonly expressed per body weight, frequently around 10 µg/kg and 10 ng/kg, with gastric-ulcer cytoprotection studied at 400–800 ng/kg in rats [1][14]. Thymosin beta-4 has been given across a wide range, for example 2–18 mg/kg intraperitoneally in a rat embolic-stroke dose-response study, with an optimal modeled near 3.75 mg/kg and 18 mg/kg giving no benefit — higher was not better [14]. Commercial "Wolverine" labeling commonly pairs the two at fixed combined masses per vial (for example ~10 mg + ~10 mg), but that ratio has no dose-finding basis [11]. The sections below lay out the BPC-157 TB-500 dosage in the literature by constituent, route, and handling practice.
Pharmacokinetics and half-life
No validated human pharmacokinetic half-life exists for either constituent at research doses, and none for the blend [14]. BPC-157's elimination half-life was reported as under 30 minutes in a rat/dog PK study [14]. Human full-length thymosin beta-4 showed dose-proportional pharmacokinetics with half-life increasing at higher doses, but no specific half-life is established for the TB-500 seven-amino-acid fragment [11][14]. The blend's pharmacokinetics are, accordingly, unknown.
Routes, reconstitution, and frequency in research handling
The routes that appear in the literature belong to the constituents, not to a tested blend protocol. The underlying rodent efficacy studies used intraperitoneal dosing predominantly; human single-agent work on full-length thymosin beta-4 and a BPC-157 safety pilot used intravenous routes; and local, topical, and oral routes appear in individual-compound models [1][11]. Subcutaneous and intramuscular are the predominant research-community routes for the blend, but those are not drawn from controlled human efficacy trials [11].